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Abstract
Introduction Functional motor disorders (FMDs) are usually categorized according to the predominant phenomenology; 
however, it is unclear whether this phenotypic classification mirrors the underlying pathophysiologic mechanisms.
Objective To compare the characteristics of patients with different FMDs phenotypes and without co-morbid neurologi-
cal disorders, aiming to answer the question of whether they represent different expressions of the same disorder or reflect 
distinct entities.
Methods Consecutive outpatients with a clinically definite diagnosis of FMDs were included in the Italian registry of func-
tional motor disorders (IRFMD), a multicenter data collection platform gathering several clinical and demographic variables. 
To the aim of the current work, data of patients with isolated FMDs were extracted.
Results A total of 176 patients were included: 58 with weakness, 40 with tremor, 38 with dystonia, 23 with jerks/facial 
FMDs, and 17 with gait disorders. Patients with tremor and gait disorders were older than the others. Patients with functional 
weakness had more commonly an acute onset (87.9%) than patients with tremor and gait disorders, a shorter time lag from 
symptoms onset and FMDs diagnosis (2.9 ± 3.5 years) than patients with dystonia, and had more frequently associated func-
tional sensory symptoms (51.7%) than patients with tremor, dystonia and gait disorders. Patients with dystonia complained 
more often of associated pain (47.4%) than patients with tremor. No other differences were noted between groups in terms 
of other variables including associated functional neurological symptoms, psychiatric comorbidities, and predisposing or 
precipitating factors.
Conclusions Our data support the evidence of a large overlap between FMD phenotypes.
Keywords Functional neurological disorders · Functional dystonia · Functional tremor · Functional weakness · Non-motor 
features · Psychogenic movement disorders
Introduction
Functional motor disorders (FMDs) consist of involuntary 
movements, posturing, gait disorder and weakness, which 
are inconsistent and incongruent with recognized neurologi-
cal diseases [1]. In clinical practice, FMDs are usually cat-
egorized according to the predominant phenomenology, as 
this approach facilitates the diagnostic work-up and choice 
of symptomatic therapeutic options. However, it is unclear 
whether this phenotypic classification mirrors the underlying 
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pathophysiologic mechanisms of the disorders. Whereas 
prior studies have provided contradictory results regarding 
possible clinical differences between psychogenic non-epi-
leptic seizures (PNES) and FMDs (for a review see [2]), only 
one study has attempted to compare different motor pheno-
types within the  group of FMDs [3]. Indeed, Gelauff et al. 
have compared a number of features including demograph-
ics, mode of onset, mood dysfunction such as depression and 
anxiety, and presence of pain and fatigue between different 
FMDs phenotypes and failed to identify any differences, 
suggesting a shared pathophysiology between these disor-
ders [3]. However, in most cases, patients had a complex 
syndrome consisting of two or more FMDs and the stratifica-
tion was based on the ‘predominant’ symptom as judged by 
the referring clinicians either provided directly on request or 
via their clinical letter, which has likely introduced an evalu-
ation bias. It has been shown that there is poor to moderate 
agreement, even between experienced movement disorder 
specialists, on the clinical diagnosis of functional hyper-
kinetic movements [4]. Their results could be also partly 
biased by the fact that data were collected through online 
questionnaire and this might have led to an under- or over-
reporting of some aspects. Finally, Gelauff et al. included 
in their analysis patients with co-morbid neurological dis-
eases [3], which might have further confounded the results, 
hampering the recognition of significant differences between 
FMDs phenotypes.
To overcome these possible limits, we explored the Italian 
registry of functional motor disorders (IRFMD) to compare 
clinical and demographic characteristics of patients with iso-
lated FMDs (i.e., patients presenting with only one FMDs 
and without co-morbid neurological disorders, aiming to 
answer the question of whether they represent different 
expressions of the same disorder or reflect distinct entities.
Methods
Data were extracted from the IRFMD managed by the 
Department of Neurosciences, Biomedicine and Movement 
Sciences, University of Verona, and by the Italian Academy 
for the Study of Parkinson’s Disease and Other Movement 
Disorders (Accademia LIMPE-DISMOV  RADAC pro-
ject) and Fondazione LIMPE. Full methods of the IRFMD 
are reported elsewhere [5].
Briefly, consecutive patients aged > 10 years, with a clini-
cally definite diagnosis of FMDs according to existing clini-
cal criteria [1] were recruited from 25 tertiary movement 
disorders centers across Italy.
Patients underwent a standardized evaluation to col-
lect several information including sex, age, education, 
mode of onset (acute, defined as abrupt with deterioration 
within a few weeks [5]; or slowly progressing), previous 
consultations and diagnoses of FMDs (general neurologist, 
neurologist specialized in movement disorders), presence of 
predisposing and precipitating factors, presence of spontane-
ous remissions, time lag from onset of symptoms to FMDs 
diagnosis, self-reported non-motor symptoms, presence of 
psychiatric and medical history including certified non-neu-
rological comorbidities, proxy of health status (calculated 
as the average of total number of non-neurological comor-
bidities), and associated functional neurological disorders 
(FNDs). All information were gathered by specific questions 
addressed to both the patients and relatives/care-givers and 
additionally by reviewing available medical records [5].
Presence of cognitive or physical impairment that pre-
cluded signing the informed consent form for participation 
in the study represented an exclusion criteria. The study was 
approved by the Ethics Committee of the Coordinator Centre 
(University of Verona, Prog. 1757CESC) and confirmed by 
the Committees of each participating center. All patients 
were informed about the nature of the study and provided 
their written consent to participate. For the aim of the cur-
rent study we selected from the IRFMD patients with iso-
lated FMDs and without co-morbid neurological disorders.
Statistical analysis
Data are expressed as mean ± standard deviation (SD) or 
median and interquartile range (IQR), as appropriate, for 
continuous variables and counts and percentages for cat-
egorical variables. One-way ANOVA was used for normally 
distributed data and Kruskal–Wallis test for non-normally 
distributed data for group comparisons. Chi-squared test or 
Fisher’s exact test were used to compare categorical vari-
ables, as appropriate.
When statistical differences between groups were found 
with a p-value < 0.05, post-hoc Tukey Test was used for pair-
wise comparisons between groups for continuous variables. 
Z-tests of Two Proportions or Fisher’s exact tests (2 × 2) 
were used accordingly for the categorical ones: we applied 
Bonferroni correction for multiple comparison. Statistical 
analyses were performed using SPSS statistical software 
(version 26; IBM-SPSS, Armonk, NY, USA).
Results
As of December 2020, 410 patients were included in the 
IRFMD [5], of whom 177 (43.2%) were identified as having 
an isolated FMDs and without neurological comorbidities. 
Of these, 1 with functional Parkinsonism was excluded and 
10 with facial FMDs were included in the ‘Jerks ‘category 
because of their low prevalence. Therefore, 176 patients 
were included in the current analysis: 58 (33%) patients 
with weakness, 40 (22.7%) with tremor, 38 (21.6%) with 
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dystonia, 23 (13.1%) with jerks/facial FMDs, and 17 (9.6%) 
with gait disorders.
The mean age of the overall cohort was 44.5 ± 16.8 years 
and females represented the large majority (69.3%). The 
overall time lag from onset of symptoms to FMDs diagnosis 
mean was 4.5 ± 5.1 years. Symptoms occurred in an acute 
onset fashion in 75% (n = 132) of cases.
Table 1 shows the comparisons of the main demographic 
and clinical variables between groups.
There were significant differences in terms of age between 
groups, with patients with tremor and gait disorders being 
older than the others (Table 1), whereas no differences were 
noted in terms of sex distribution.
Patients with functional weakness had more commonly 
an acute onset (87.9%) as compared with patients with 
tremor (60%, p < 0.05) and gait disorders (52.9%, p < 0.05), 
a shorter time lag from onset of symptoms and FMDs diag-
nosis (mean ± SD 2.9 ± 3.5, median 1.5, IQR 0.75–5; years) 
than patients with dystonia (mean ± SD 6.4 ± 6.3, median 
4.5, IQR 2–9, years) and had more commonly associated 
sensory functional symptoms (51.7%) than patients with 
tremor (7.5%, p < 0.05), dystonia (5.3%, p < 0.05) and gait 
disorders (11.8%, p < 0.05) (Table 1).
Although patients with dystonia were less likely to have 
non-neurological comorbidities, the total number of comor-
bidities, which can be considered as a proxy of health sta-
tus, did not differ between groups (Table 1). Patients with 
dystonia complained more often of associated pain (47.4%) 
than patients with tremor (17.5%, p < 0.05). The first diag-
nosis of FMDs, before the patients’ enrollment in this study, 
was performed by a movement disorder specialist in over 
70% of patients in each phenotypic group except for func-
tional weakness, which was diagnosed in 40% of the patients 
by a general neurologist. No other differences were noted 
between groups in terms of associated FNDs, self-reported 
non-motor symptoms, psychiatric comorbidities, predispos-
ing and precipitating factors (Table 1).
Discussion
In the current study, we aimed to compare several demo-
graphic and clinical variables in patients with different iso-
lated FMDs phenotypes. Patients with FMDs often have 
multiple phenomenologies [5] and clinicians have to make 
a judgment on which one is “predominant”, likely introduc-
ing a bias when attempting to compare different phenotypes. 
To overcome this limit, we enrolled patients with isolated 
FMDs and without co-morbid neurological disorders, aim-
ing to answer the question of whether they could represent 
different expressions of the same disorder or reflect distinct 
entities.
All groups displayed similar rates of psychiatric and other 
non-neurological comorbidities, associated FNDs, predis-
posing and precipitating factors and self-reported non-motor 
symptoms, with the exception of pain that, as expected [6, 
7] was found to be more common in patients with functional 
dystonia than in patients with tremor, and of sensory func-
tional symptoms that were commoner in patients with weak-
ness than in patients with other phenotypes [8]. These results 
might support the concept that common mechanisms might 
underlie different FMDs, as also suggested by the frequent 
overlap of different FMDs in the same patient, as observed 
in a previous study [3, 7].
As mentioned above, patients with dystonia had higher 
rates of pain and this might be the result of a dissociation 
between the sensory-discriminative and cognitive-affective 
components of pain (increased pain tolerance together with 
a normal pain threshold) [7]. We also found that functional 
tremor and gait disorders were the most frequent FMDs 
in older patients which is in line with a study focusing on 
FMDs in the elderly population [9]. The reasons why this 
happens are unclear. As action tremor and gait disturbances 
(determined by neurological or orthopedic conditions) are 
common in this age group, we might speculate that expo-
sure to these symptoms in the elderly population might be 
responsible of illness beliefs which are meant to be a crucial 
factor in FMDs generation [10]. A significant impact of dis-
ease modeling within the family or close friendship has been 
demonstrated in FMDs [11], and the same concept might be 
applicable in a wider sense considering the common knowl-
edge that tremor, for instance due to Parkinson disease, and 
gait disturbances occur in elderly age.
In line with previous studies, patients with functional 
weakness were more likely to have an acute onset as well as 
associated sensory functional symptoms in the affected body 
region than patients with other phenotypes. Acute onset of 
functional weakness has been also reported by a previous 
study, in which different factors closely associated with the 
onset could be identified [12]. These included dissociative 
symptoms, with the hypothesis that functional weakness 
could therefore be a form of ‘hemi-depersonalisation’ or 
compartmentalisation, or physical injuries, in which the 
relationship with the functional weakness could be in terms 
of immobility and/or increased attention paid to a body part 
[12]. It is therefore important to evaluate associated fac-
tors at onset, as these might represent clues to identify the 
mechanism of the development of functional weakness [12].
The frequent co-occurrence of functional weakness and 
sensory symptoms is intriguing and might be explained 
by a common pathophysiological mechanism:  hypoac-
tive subcortical circuits controlling sensorimotor function 
might drive deficient voluntary motor behavior and sensory 
loss, similar to what happens in patients with motor neglect 
[8]. This is different from what is construed to occur in the 
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Table 1  Demographic and clinical features of different FMDs phenotypes
FMDs functional motor disorders, FND functional neurological disorders; °Before enrollment, SD standard deviation, IQR interquartile range; 
statistical testing: one-way ANOVA (A), Kruskal–Wallis test (K), Chi-square test (C), Fisher’s exact test (F); significant values at p < 0.05 in 
bold. §Health status = calculated as the average of total number of non-neurological comorbidities. Age = patient’s age at the enrollment in this 
study and our diagnosis of FMDs
Post-hoc comparisons, p < 0.05: #vs tremor; *vs gait disorders; §vs dystonia; @vs weakness
a The education variable reported 19 missing
Variable Total Weakness Tremor Dystonia Jerks Gait disorders Group comparison
Patients, n (%) 176 58 (33) 40 (22.7) 38 (21.6) 23 (13.1) 17 (9.6)
Gender, n (%)
 Male 16 (27.6) 16 (40) 13 (34.2) 5 (21.7) 4 (23.5) 0.495C
 Female 42 (72.4) 24 (60) 25 (65.8) 18 (78.3) 13 (76.5)
Age, y, mean (SD) 40.1 (13.8)# * 49.6 (18.1) 42.4 (15.8)* 40.2 (17.5)* 57.6 (15.9) <0.001A
Education, y, mean (SD)a 12.1 (2.7) 11 (3.7) 12.4 (3.9) 12.3 (3.4) 9.9 (5) 0.136K
 , median (IQR, Q1-Q3) 13 (10–13) 13 (8–13) 13 (8–15) 13 (9.5–15.8) 10.5 (5–13)
Previous consultations, n (%) 42 (72.4) 29 (72.5) 33 (86.8) 13 (56.5) 13 (76.5) 0.129F
Time lag from onset of symptoms to
FMDs diagnosis, years, mean (SD)
2.9 (3.5)§ 4.6 (5.6) 6.4 (6.3) 5.1 (5.1) 4 (4.1) 0.005K
 , median (IQR, Q1-Q3) 1.5 (0.75–5) 3 (1–6) 4.5 (2–9) 3 (2–7) 3 (1.5–4.5)
FMD onset, n (%)
 Acute 51 (87.9) 24 (60)@ 29 (76.3) 19 (82.6) 9 (52.9)@ 0.004F
 Slowly progressing 7 (12.1) 16 (40) 9 (23.7) 4 (17.4) 8 (47.1)
FMD spontaneous remissions, (%) 33 (56.9) 21 (52.5) 19 (50) 16 (69.6) 7 (41.2) 0.429C
Diagnosis of FMDs, n (%)°
 General neurologist 23 (39.7) 3 (7.5)@ 2 (5.3)@ 2 (8.7) 4 (23.5) <0.001F
 Neurologist specialized in movement 
disorders
30 (51.7) 35 (87.5)@ 34 (89.5)@ 19 (82.6) 12 (70.6) <0.001F
Self-reported non-motor symptoms, n (%)
 Anxiety 22 (37.9) 24 (60) 16 (42.1) 10 (43.5) 6 (35.3) 0.232C
 Fatigue 21 (36.2) 9 (22.5) 13 (34.2) 6 (26.1) 4 (23.5) 0.565C
 Pain 22 (37.9) 7 (17.5) 18 (47.4)# 5 (21.7) 5 (29.4) 0.040C
 Migraine 11(19) 6 (15) 8 (21.1) 2 (8.7) 2 (11.8) 0.763F
 Insomnia 12 (20.7) 10 (25) 5 (13.2) 2 (8.7) 5 (29.4) 0.325F
 Panic attacks 8 (13.8) 5 (12.5) 5 (13.2) 4 (17.4) 0 (0) 0.535F
 Depersonalization/derealization 7 (12.1) 2 (5) 4 (10.5) 4 (17.4) 0 (0) 0.322F
Non-neurological comorbidities, n (%) 26 (44.8) 20 (50) 7 (18.4))# 7 (30.4) 8 (47.1) 0.029C
 Health  status§, mean (SD) 1.8 (0.9) 1.8 (1.1) 1.4 (0.7) 1.4 (0.7) 1.7 (0.7) 0.735K
 Median (IQR, Q1-Q3) 1.5 (1–2.25) 1 (1–2.75) 1 (1–2) 1 (1–2) 2 (1–2)
Associated FND, n (%)
 Sensory functional symptoms 30 (51.7)#§* 3 (7.5) 2 (5.3) 5 (21.7) 2 (11.8) <0.001F
 Non-epileptic seizures 8 (13.8) 3 (7.5) 6 (15.8) 4 (17.4) 0 (0) 0.344F
 Visual functional symptoms 4 (6.9) 2 (5) 0 (0) 0 (0) 3 (17.6) 0.063F
 Cognitive functional symptoms 6 (10.3) 3 (7.5) 2 (5.3) 0 (0) 1 (5.9) 0.617F
 Fibromyalgia 3 (5.2) 0 (0) 3 (7.9) 1 (4.3) 0 (0) 0.402F
 Irritable bowel syndrome 3 (5.2) 1 (2.5) 0 (0) 1 (4.3) 1 (5.9) 0.565F
Psychiatric comorbidities, n (%) 18 (31) 12 (30) 13 (34.2) 9 (39.1) 4 (23.5) 0.864C
Predisposing factors, n (%)
 Childhood psychological trauma 3 (5.2) 1 (2.5) 2 (5.3) 1 (4.3) 1 (5.9) 0.943F
 Childhood physical trauma 0 (0) 0 (0) 1 (2.6) 1 (4.3) 0 (0) 0.290F
Precipitating factors, n (%)
 Psychological trauma 14 (24.1) 8 (20) 15 (39.5) 4 (17.4) 1 (5.9) 0.073F
 Physical trauma 5 (8.6) 2 (5) 8 (21.1) 2 (8.7) 1 (5.9) 0.217F
 Surgery 7 (12.1) 2 (5) 6 (15.8) 3 (13) 3 (17.6) 0.500F
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context of functional symptoms characterized by excessive 
motor output, in which increased activation of areas impli-
cated in self-awareness, self-monitoring, and active motor 
inhibition has been observed [13].
People with functional weakness also had a shorter diag-
nostic time lag and were diagnosed more frequently by 
general neurologists. Altogether, these features highlight 
that general neurologists are more familial with this type 
of clinical presentation and are more confident in perform-
ing the diagnosis of functional weakness in comparisons 
with other phenotypes. The consequence of this might be 
reflected by the longer diagnostic delay, especially for the 
group with functional dystonia, which call for an effort to 
increase knowledge about FMDs among general neurologists 
in view of the fact that diagnostic delay is a strong predictor 
of poor prognosis in this population [5].
We found comparable and low rates of predisposing fac-
tor as well as of psychiatric comorbidities between groups. 
It is conceivable that childhood psychological/physical 
trauma might have a weaker impact in patients with adult-
onset FMDs, but we should also highlight that formal psy-
chological and psychiatric evaluations were not performed 
in our study. This might have led to an underestimation of 
psychological trauma and psychiatric disturbances in com-
parison to previous studies [3, 14]. Supporting this hypoth-
esis, we note that, for instance, self-reported anxiety was 
more common than a formal diagnosis of mood disorder 
made by a psychiatrist in all FMDs groups. However, even 
in case of higher rates of a formal psychiatric diagnosis, one 
would expect them to evenly distribute across different phe-
notypes, thus not explaining why one patient might develop 
one or another motor disturbance. Precipitating factors were 
statistically comparable among phenotypes, even though 
patients with dystonia showed higher rates of both physi-
cal and psychological trauma. Whereas the link between 
physical trauma and dystonia in the same body part seems 
more straightforward, the relationship between psychologi-
cal trauma and dystonia is less clear. A previous study also 
found that patients with functional dystonia had high rates of 
psychological stressors [15], which reinforces the need for a 
comprehensive evaluation of these patients.
We acknowledge some limitations. Although we identi-
fied a large overlap between different FMDs phenotypes, 
our comparisons are only based on clinical features, which 
prevents drawing definitive conclusions about common 
pathophysiological mechanisms. Therefore, future stud-
ies, using for instance neurophysiological and imaging 
techniques, are needed to deepen the pathophysiological 
mechanisms of FMDs [16]. Furthermore, our data cannot 
answer the question about why some patients may develop 
a phenotype instead of another. A prior study reported 
some gender-driven differences between FMDs phenotype, 
with functional dystonia being more common in females 
and a trend for gait disturbance being commoner in males 
[17]. However, it is likely that additional features drive the 
development of a specific phenotype.
We also note that recruitment was performed in ter-
tiary-care, movement disorder centers and a proportion of 
patients, for instance with functional weakness, might have 
not been referred to the participating centers. Moreover, 
for the aim of the current study we only selected patients 
with isolated FMDs. For these reasons, prevalence figures 
of different phenotypes reported in this study should not be 
intended as representative of the entire population of FMDs.
Moreover, we could not determine the severity of 
recorded symptoms as we did not employ any rating 
instrument for them (i.e. pain). Finally, the frequency of 
psychological stressors might be underestimated because 
of the failure of the providers not to ask to specific ques-
tions. In-clinic interviews are prone to ascertainment bias 
as demonstrated by the detection of higher rates of psy-
chological stressors in anonymous surveys [18]. Previous 
studies have reported a higher frequency of psychological 
stressors including physical abuse and sexual assault in 
FMDs compared to our study [19], but we are unaware of 
any research looking at possible differences between phe-
notypes. Future prospective studies are therefore needed to 
clarify how these factors differ among different FMDs phe-
notypes to further develop specific management strategies.
In summary, our data confirm the evidence of a large 
overlap between FMDs phenotypes. If the clinical catego-
rization according to the main motor phenotype remains 
valuable to guide the diagnostic work-up, it might not be 
useful to speculate about the underlying pathophysiology 
nor to categorize and measure outcome in FMDs pheno-
types. This finding is supported by the significant overlap 
in terms of multiple non-motor symptoms which might be 
equally detrimental to patients’ functioning and quality 
of life and should be addressed in all FMDs patients [3]. 
The difference in the age at onset between groups requires 
future studies to explain the mechanisms driving the devel-
opment of a certain phenotype, upon which planning of 
treatment options is partly dependent [20, 21].
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00415- 021- 10583-w.
Funding  Open access funding provided by Università degli Studi di 
Verona within the CRUI-CARE Agreement.
Declarations 
Conflicts of interest The authors declare that they have no conflict of 
interest. 
Ethical approval The study was approved by the Ethics Committee of 
the Coordinator Centre (University of Verona, Prog. 1757CESC) and 
confirmed by the Committees of each participating center.
 Journal of Neurology
1 3
Consent to participate All patients were informed about the nature of 
the study and provided their written consent to participate.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett 
M, LaFaver K, LaFrance WC Jr, Lang AE, Nicholson T, Nielsen 
G, Reuber M, Voon V, Stone J, Morgante F (2018) Current con-
cepts in diagnosis and treatment of functional neurological disor-
ders. JAMA Neurol 75:1132–1141. https:// doi. org/ 10. 1001/ jaman 
eurol. 2018. 1264
 2. Erro R, Brigo F, Trinka E, Turri G, Edwards MJ, Tinazzi M 
(2016) Psychogenic nonepileptic seizures and movement disor-
ders: a comparative review. Neurol Clin Pract 6:138–149. https:// 
doi. org/ 10. 1212/ CPJ. 00000 00000 000235
 3. Gelauff JM, Rosmalen JGM, Gardien J, Stone J, Tijssen MAJ 
(2020) Shared demographics and comorbidities in different func-
tional motor disorders. Parkinsonism Relat Disord 70:1–6. https:// 
doi. org/ 10. 1016/j. parkr eldis. 2019. 11. 018
 4. Morgante F, Edwards MJ, Espay AJ, Fasano A, Mir P, Martino D 
(2012) Diagnostic agreement in patients with psychogenic move-
ment disorders. Mov Disord. 27:548–552
 5. Tinazzi M, Morgante F, Marcuzzo E, Erro R, Barone P, Ceravolo 
R, Mazzucchi S, Pilotto A, Padovani A, Romito LM, Eleopra R, 
Zappia M, Nicoletti A, Dallocchio C, Arbasino C, Bono F, Pas-
carella A, Demartini B, Gambini O, Modugno N, Olivola E, Di 
Stefano V, Albanese A, Ferrazzano G, Tessitore A, Zibetti M, 
Calandra-Buonaura G, Petracca M, Esposito M, Pisani A, Man-
ganotti P, Stocchi F, Coletti Moja M, Antonini A, Defazio G, 
Geroin C (2020) Clinical correlates of functional motor disorders: 
an Italian multicenter study. Mov Disord Clin Pract 7:920–929. 
https:// doi. org/ 10. 1002/ mdc3. 13077
 6. Ibrahim NM, Martino D, van de Warrenburg BP, Quinn NP, Bha-
tia KP, Brown RJ, Trimble M, Schrag A (2009) The prognosis 
of fixed dystonia: a follow-up study. Parkinsonism Relat Disord 
15:592–597. https:// doi. org/ 10. 1016/j. parkr eldis. 2009. 02. 010
 7. Morgante F, Matinella A, Andrenelli E, Ricciardi L, Allegra C, 
Terranova C, Girlanda P, Tinazzi M (2018) Pain processing in 
functional and idiopathic dystonia: an exploratory study. Mov 
Disord 33:1340–1348. https:// doi. org/ 10. 1002/ mds. 27402
 8. Vuilleumier P, Chicherio C, Assal F, Schwartz S, Slosman D, Lan-
dis T (2001) Functional neuroanatomical correlates of hysterical 
sensorimotor loss. Brain 124:1077–1090. https:// doi. org/ 10. 1093/ 
brain/ 124.6. 1077
 9. Batla A, Stamelou M, Edwards MJ, Pareés I, Saifee TA, Fox Z, 
Bhatia KP (2013) Functional movement disorders are not uncom-
mon in the elderly. Mov Disord 28:540–543. https:// doi. org/ 10. 
1002/ mds. 25350
 10. Edwards MJ (2017) Neurobiologic theories of functional neuro-
logic disorders. Handb Clin Neurol 139:131–137. https:// doi. org/ 
10. 1016/ B978-0- 12- 801772- 2. 00012-6
 11. Pellicciari R, Superbo M, Gigante AF, Livrea P, Defazio G (2014) 
Disease modeling in functional movement disorders. Parkinson-
ism Relat Disord 20:1287–1289. https:// doi. org/ 10. 1016/j. parkr 
eldis. 2014. 09. 017
 12. Stone J, Warlow C, Sharpe M (2012) Functional weakness: clues 
to mechanism from the nature of onset. J Neurol Neurosurg Psy-
chiatry 83:67–69. https:// doi. org/ 10. 1136/ jnnp- 2011- 300125
 13. Baizabal-Carvallo JF, Hallett M, Jankovic J (2019) Pathogenesis 
and pathophysiology of functional (psychogenic) movement dis-
orders. Neurobiol Dis 127:32–44. https:// doi. org/ 10. 1016/j. nbd. 
2019. 02. 013
 14. Epstein SA, Maurer CW, LaFaver K, Ameli R, Sinclair S, Hallett 
M (2016) Insights into chronic functional movement disorders: 
the value of qualitative psychiatric interviews. Psychosomatics 
57:566–575. https:// doi. org/ 10. 1016/j. psym. 2016. 04. 005
 15. Schrag A, Trimble M, Quinn N (2004) Bhatia K (2004) The 
syndrome of fixed dystonia: an evaluation of 103 patients. Brain 
127:2360–2372. https:// doi. org/ 10. 1093/ brain/ awh262
 16. Drane DL, Fani N, Hallett M, Khalsa SS, Perez DL, Roberts NA 
(2020) A framework for understanding the pathophysiology of 
functional neurological disorder. CNS Spectr 2020:1–7. https:// 
doi. org/ 10. 1017/ S1092 85292 00017 89
 17. Baizabal-Carvallo JF, Jankovic J (2019) Gender differences in 
functional movement disorders. Mov Disord Clin Pract 7:182–
187. https:// doi. org/ 10. 1002/ mdc3. 12864
 18. Smith SG, Zhang X, Basile KC, Merrick MT, Wang J, Kresnow 
M, Chen J (2018) The National Intimate Partner and Sexual Vio-
lence Survey: 2015 data brief—updated release. National Center 
for Injury Prevention and Control, Centers for Disease Control 
and Prevention, Atlanta, GA. Available at https:// stacks. cdc. gov/ 
view/ cdc/ 60893
 19. Kletenik I, Sillau SH, Isfahani SA, LaFaver K, Hallett M, Berman 
BD (2019) Gender as a risk factor for functional movement disor-
ders: the role of sexual abuse. Mov Disord Clin Pract 7:177–181. 
https:// doi. org/ 10. 1002/ mdc3. 12863
 20. Dallocchio C, Tinazzi M, Bombieri F, Arnó N, Erro R (2016) 
Cognitive behavioural therapy and adjunctive physical activ-
ity for functional movement disorders (conversion disorder): a 
pilot, single-blinded. Randomized Study Psychother Psychosom 
85:381–383. https:// doi. org/ 10. 1159/ 00044 6660
 21. Gandolfi M, Riello M, Bellamoli V, Bombieri F, Geroin C, Di 
Vico IA, Tinazzi M (2021) Motor and non-motor outcomes after 
a rehabilitation program for patients with functional motor disor-
ders: a prospective, observational cohort study. NeuroRehabilita-
tion. https:// doi. org/ 10. 3233/ NRE- 201617
Journal of Neurology 
1 3
Authors and Affiliations
Michele Tinazzi1 · Christian Geroin1  · Enrico Marcuzzo1 · Sofia Cuoco2 · Roberto Ceravolo3 · Sonia Mazzucchi3 · 
Andrea Pilotto4,5 · Alessandro Padovani4 · Luigi Michele Romito6 · Roberto Eleopra6 · Mario Zappia7 · 
Alessandra Nicoletti7 · Carlo Dallocchio8 · Carla Arbasino8 · Francesco Bono9 · Giuseppe Magro9 · 
Benedetta Demartini10 · Orsola Gambini10 · Nicola Modugno11 · Enrica Olivola11 · Laura Bonanni12 · 
Elisabetta Zanolin13 · Alberto Albanese14 · Gina Ferrazzano15 · Rosa De Micco16 · Leonardo Lopiano17 · 
Giovanna Calandra‑Buonaura18,19 · Martina Petracca20 · Marcello Esposito21 · Antonio Pisani22,23 · 
Paolo Manganotti24 · Lucia Tesolin25 · Francesco Teatini25 · Tommaso Ercoli26 · Francesca Morgante27,28 · 
Roberto Erro2
1 Neurology Unit, Movement Disorders Division, Department 
of Neurosciences, Biomedicine and Movement Sciences, 
University of Verona, P.le Scuro 10, 37134 Verona, Italy
2 Center for Neurodegenerative Diseases (CEMAND), 
Department of Medicine, Surgery and Dentistry-Scuola 
Medica Salernitana, University of Salerno, Baronissi, SA, 
Italy
3 Neurology Unit, Department of Clinical and Experimental 
Medicine, University of Pisa, Pisa, Italy
4 Neurology Unit, Department of Clinical and Experimental 
Sciences, University of Brescia, Brescia, Italy
5 FERB Onlus, Ospedale S. Isidoro, Trescore Balneario, 
Bergamo, Italy
6 Parkinson and Movement Disorders Unit, Fondazione IRCCS 
Istituto Neurologico Carlo Besta, Milan, Italy
7 Department G.F. Ingrassia, Section of Neurosciences, 
University of Catania, Catania, Italy
8 Department of Medical Area, Neurology Unit, ASST Pavia, 
Pavia, Italy
9 Botulinum Toxin Center, Neurology Unit A.O.U. Mater 
Domini, Catanzaro, Italy
10 Aldo Ravelli Research Center for Neurotechnology 
and Experimental Brain Therapeutics, Department of Health 
Sciences, University of Milan, Milan, Italy
11 IRCCS Neuromed, Pozzilli, Italy
12 Department of Neuroscience, Imaging and Clinical Sciences, 
University G. D’Annunzio, Chieti-Pescara, Italy
13 Unit of Epidemiology and Medical Statistics, Department 
of Diagnostics and Public Health, University of Verona, 
Verona, Italy
14 Department of Neurology, IRCCS Humanitas Research 
Hospital, Rozzano Milan, Italy
15 Department of Human Neurosciences, Università La 
Sapienza, Rome, Italy
16 Department of Advanced Medical and Surgery Sciences, 
University of Campania-Luigi Vanvitelli, Naples, Italy
17 Department of Neuroscience-Rita Levi Montalcini, 
University of Turin, Turin, Italy
18 Department of Biomedical and Neuromotor Sciences, 
University of Bologna, Bologna, Italy
19 IRCCS, Institute of Neurological Sciences of Bologna, 
Bologna, Italy
20 Movement Disorder Unit, Fondazione Policlinico 
Universitario A. Gemelli IRCCS, Rome, Italy
21 Clinical Neurophysiology Unit, Cardarelli Hospital, Naples, 
Italy
22 IRCCS Mondino Foundation, Pavia, Italy
23 Department of Brain and Behavioral Sciences, University 
of Pavia, Pavia, Italy
24 Clinical Neurology Unit, Department of Medical, Surgical 
and Health Services, University of Trieste, Trieste, Italy
25 Functional Movement Disorders Outpt. Clinic, Clinical 
Neurology and Stroke Unit Department, Central Country 
Hospital, Bolzano, Italy
26 Department of Medical Sciences and Public Health, 
University of Cagliari, Cagliari, Italy
27 Neurosciences Research Centre, Molecular and Clinical 
Sciences Neurosciences Research Centre, Molecular 
and Clinical Sciences Research Institute, St George’s 
University of London, London, UK
28 Department of Experimental and Clinical Medicine, 
University of Messina, Messina, Italy
